Welcome! Login | Register
 

Monfredo: Civics Education…A Relic of The Past or Critical Componet to Our Future—According to the National Assessment of Educational Progress

What to Watch For: Patriots vs. Bears—The Patriots welcome the Bears to Gillette Stadium…

Holy Cross at Lafayette Football Preview—Holy Cross visits conference rival Lafayette on Saturday

$73 Million North High has 31% Dropout Rate—In hopes of improving the dropout rate and…

Tom Finneran: I’m Joe Citizen and I Disapprove These Messages—We’re less than two weeks away from Election…

McGovern and Markey Visit WPI to Tour Robotics Lab—U.S. Representative Jim McGovern and U.S. Senator Ed…

Holy Cross Men’s Basketball Predicted to Finish 3rd in Patriot League—Holy Cross Picked to finish 3rd in Patriot…

Fattman Slams Abraham Over Mismanagement—Stephanie Fattman, appearing Tuesday on The Jordan Levy…

See the Great Pumpkin Fest at the Ecotarium with Your Woo Card—The weekend is fast approaching, and GoLocalWorcester brings…

10 Best Loved Bacon Dishes in Worcester—We all love bacon.

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.